[ClickPress, Thu Jul 11 2019] Although the dual antiplatelet therapy
reduces the risks of thromboembolic conditions, it is also associated with a major risk of bleeding that can sometimes be fatal, which may create hindrance in the growth of dual antiplatelet therapy
Benefit of switching dual antiplatelet therapy
after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study.
Exclusion criteria were active bleeding, shock, end-stage malignant diseases, kidney failure with dialysis therapy, or any contraindication for dual antiplatelet therapy
. GRACE, CRUSADE, and TIMI scores were evaluated, and patients were stratified into risk categories according to previously described criteria.
We found that majority of our patients (>60%) were prescribed dual antiplatelet therapy
, mainly a combination of Clopidogrel 75 mg plus aspirin 75mg, for long term secondary prevention of stroke.
Impact of proton-pump inhibitors on the pharmacodynamic effect and clinical outcomes in patients receiving dual antiplatelet therapy
after percutaneous coronary intervention: A Propensity score analysis.
Univariate analysis showed two risk factors for operative stroke: high-grade stenosis or occlusion of the contralateral carotid artery (OR 3.1154, 95% CI 1.1620 to 8.3522, p = 0.0239) and absence of previous dual antiplatelet therapy
(OR 3.1154, 95% CI 1.8537 to 526.4871, p = 0.0169).
The primary mechanism of restenosis in a stented coronary artery is neointimal hyperplasia after intimal injury with inflammatory reaction.,, Reportedly, the drug-eluting stent (DES) can significantly reduce restenosis as compared to bare-metal stent (BMS) implantation. Even in the era of second- and third-generation DES, BMS plays a role in PCI, especially in patients who cannot tolerate the recommended duration of dual antiplatelet therapy
due to noncompliance, the need for noncardiac surgery, or increased risk for bleeding.
The patient was commenced on dual antiplatelet therapy
and her clozapine which had been stopped on admission was restarted.
The patient was started on dual antiplatelet therapy
(DAPT) with aspirin 81 mg and Plavix 75 mg.
Individual proton pump inhibitors and outcomes in patients with coronary artery disease on dual antiplatelet therapy
: a systematic review.